Trial Profile
FOLFIRI + Erbitux versus alternating FOLFIRI + Erbitux/FOLFOX + Erbitux to patients with RAS wild type metastatic colorectalcancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Feb 2023
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Calcium carbonate; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
- Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Rectal cancer
- Focus Pharmacogenomic; Therapeutic Use
- Acronyms Nordic-8
- 29 Oct 2020 Status changed from active, no longer recruiting to completed.
- 05 Dec 2019 This trial is completed in Sweden (Global End Date: 1 Mar 2019), according to European Clinical Trials Database record.
- 21 Oct 2019 This trial has been completed in Denmark As per EudraCT Record